Skip to main content
×
Login
Submit a Manuscript
Home
Journal
Current Issue
Archive
For Authors
Column Series
Research & Insight
Special Reports
Subscribe
Resources
Blogs
Expert Insights
Latest News
Pathways Beyond Oncology
Topics
Comparative Effectiveness Research
Cost-Effectiveness Research
COVID-19 Updates
Guideline Updates
Health Economics and Outcomes Research
Health Technology
Real-World Data
Reimbursement
Value-Based Care
Specialties
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Biosimilars
Bladder Cancer
Breast Cancer
CAR-T Therapies
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Immuno-Oncology
Kidney Cancer
Liver Cancer
Lung Cancer
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Supportive Care
Excellence Forums
Mantle Cell Lymphoma Excellence Forum
Conferences
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ACCC Annual Meeting & Cancer Center Business Summit
ASCO Genitourinary Cancers Symposium
ASH Annual Meeting and Exposition
Oncology CME
About
About Us
Contact
Special Reports
Special Reports
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
January 14, 2021
While there is no cure for MM, a number of treatments are in the research and development pipeline. Clinicians are particularly challenged to treat relapsed or refractory MM.
Special Reports
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
January 14, 2021
While there is no cure for MM, a number of treatments are in the research and development pipeline. Clinicians are…
Special Reports
New Approved Treatments and Indications in Oncology
December 30, 2020
As the FDA has implemented new programs to streamline its review and approval processes, a total of 47 novel drugs were…
Special Reports
Product Perspectives: Brukinsa (Zanubrutinib) for Mantle Cell Lymphoma (Sponsored)
December 17, 2020
An interview with David Andorsky, MD, Rocky Mountain Cancer Centers, Boulder, Colorado.
Special Reports
Overview of the Updated NCCN Guidelines on Ovarian Cancer
Deborah Abrams Kaplan, June 17, 2020
The most recent updates in ovarian cancer treatment considerations are highlighted, including notes on staging and…
Special Reports
Highlights From the 2019 Oncology Clinical Pathways Congress
JCP Editors, November 19, 2019
Coverage of the 2019 Oncology Clinical Pathways Congress includes multiple interviews with faculty members and…
Special Reports
Clinical Pathways Updates in Multiple Myeloma: Addressing Resistance and Relapse
Deborah Abrams Kaplan, September 20, 2019
This special report notes the various resistance and relapse considerations in pathways for multiple myeloma, as well…
Special Reports
Updates in Treatment and Clinical Pathways for Skin Cancer
JCP Editors, June 20, 2019
This article reviews the leading types of skin cancers in the US in terms of prevalence, treatment guidelines, and…
Special Reports
Clinical Pathways for Breast Cancer: A Case Study
JCP Editors, June 18, 2019
Breast cancer represents 15.2% of all newly diagnosed US cancer cases and is the second most common cancer in women,…
Special Reports
New Approved Treatments and Indications in Oncology
JCP Editors, December 18, 2018
As FDA has implemented new programs to streamline its review and approval processes, a total of 55 novel drugs were…
Special Reports
New Approved and Emerging Treatments in Oncology
December 15, 2017
Pagination
Current page
1
Page
2
Next page
››
Last page
Last »
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top